- Home
- RXRX vs IBRX Comparison
RXRX vs IBRX Comparison
Compare RXRX & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- IBRX
- Stock Information
- Founded
- RXRX 2013
- IBRX 2014
- Country
- RXRX United States
- IBRX United States
- Employees
- RXRX N/A
- IBRX N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXRX Health Care
- IBRX Health Care
- Exchange
- RXRX Nasdaq
- IBRX Nasdaq
- Market Cap
- RXRX 2.4B
- IBRX 2.3B
- IPO Year
- RXRX 2021
- IBRX N/A
- Fundamental
- Price
- RXRX $5.77
- IBRX $2.55
- Analyst Decision
- RXRX Buy
- IBRX Strong Buy
- Analyst Count
- RXRX 5
- IBRX 5
- Target Price
- RXRX $7.00
- IBRX $10.20
- AVG Volume (30 Days)
- RXRX 24.9M
- IBRX 9.3M
- Earning Date
- RXRX 08-05-2025
- IBRX 08-05-2025
- Dividend Yield
- RXRX N/A
- IBRX N/A
- EPS Growth
- RXRX N/A
- IBRX N/A
- EPS
- RXRX N/A
- IBRX N/A
- Revenue
- RXRX $64,596,000.00
- IBRX $56,600,000.00
- Revenue This Year
- RXRX $19.96
- IBRX $567.98
- Revenue Next Year
- RXRX $61.39
- IBRX $160.56
- P/E Ratio
- RXRX N/A
- IBRX N/A
- Revenue Growth
- RXRX 30.14
- IBRX 4227.22
- 52 Week Low
- RXRX $3.79
- IBRX $1.83
- 52 Week High
- RXRX $12.36
- IBRX $7.48
- Technical
- Relative Strength Index (RSI)
- RXRX 53.41
- IBRX 47.18
- Support Level
- RXRX $5.41
- IBRX $2.45
- Resistance Level
- RXRX $5.82
- IBRX $2.94
- Average True Range (ATR)
- RXRX 0.32
- IBRX 0.14
- MACD
- RXRX -0.04
- IBRX 0.02
- Stochastic Oscillator
- RXRX 52.78
- IBRX 36.07
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.